Evaluating cancer-associated fibroblasts using PET imaging
Official title: Evaluation Using FAPI-PET Targeting Cancer-associated Fibroblasts
Run by Osaka University · NCT05442151 · Data updated 2026-11-12
This study is testing a new type of PET imaging to see if it can better help doctors understand and treat pancreatic and gastric cancer by looking at the supportive tissue around the tumors.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Osaka University Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Suita, Osaka) |
| Status | Recruiting |
| Started | May 9, 2022 |
| Main results expected | March 31, 2026 |
| Study ends | March 31, 2026 |
| Registry record updated | July 31, 2025 |
| Trial ID | NCT05442151 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients diagnosed with malignant tumors or those suspected of having such tumors who have undergone prior imaging.
✕Probably not a fit
Patients who are pregnant, pediatric patients requiring sedation, or those deemed inappropriate for the study will not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the use of a specific PET imaging agent, [18F] FAPI-74, to assess cancer-associated fibroblasts in patients diagnosed with malignant tumors, particularly pancreatic and gastric cancers. The approach involves comparing the results of this imaging technique with traditional FDG-PET/CT scans to gain a deeper understanding of the tumor pathology. By focusing on the cancer stroma, which constitutes a significant portion of tumors, the study aims to enhance diagnostic accuracy and treatment planning for affected patients.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic methods for cancer, allowing for more tailored and effective treatment strategies.
How similar studies have gone: Other studies using similar PET imaging techniques have shown promise, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients who meet any of the following conditions. 1. Patients who have been diagnosed with malignant tumors or suspected of having malignant tumors and have CT or FDG-PET examination. 2. Patients who have been diagnosed with malignant tumor and are scheduled to receive or have undergone anticancer treatment such as chemotherapy or radiation therapy. 3. Patients suspected of recurrence by clinical findings or diagnostic imaging such as CT or FDG-PET after treatment of malignant tumor Exclusion Criteria: 1. Pregnant women or patients who may be pregnant 2. Pediatric patients requiring sedation 3. Those who are judged to be inappropriate as subjects.
Where it's running
-
Osaka University Hospital
Suita, Osaka, Japan Recruiting
Study contacts
- Study coordinator: Tadashi Watabe, M.D., Ph.D.
- Email: watabe@tracer.med.osaka-u.ac.jp
- Phone: +81-6-6879-3461
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HR20013 for preventing nausea and vomiting in cancer patients receiving chemotherapy
This real-world study tests whether HR20013 helps prevent nausea and vomiting in adults with cancer who are getting chemotherapy.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
-
Ready for Safe Cancer Treatment (RESET): A comprehensive perioperative program for surgical patients
The RESET program tests a structured, multidisciplinary perioperative plan to improve safety and recovery for adults having planned cancer surgery and older adults having planned non cancer-related surgery.
-
How environment and biology together predict health, aging, and death
Researchers are following adults to see how living conditions and biology together relate to aging and life expectancy, by linking personal health data with environmental and social information over time.
-
Metastatic liver cancer patient registry from multiple Chinese centers
This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.
-
TriAdeno and N-803 vaccine in early prostate cancer on active surveillance
A vaccine combo called TriAdeno plus the N-803 drug is being tested to see if it can help slow or stop growth in men with early-stage, low- to intermediate-risk prostate cancer who are being watched rather than treated right away.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.